AngII (angiotensin II) may contribute to cardiovascular risk in obesity via adverse effects on insulin sensitivity and endothelial function. In the present study, we examined the effects of ARB (angiotensin receptor blocker) therapy (losartan, 100 mg/day) on insulin sensitivity and endothelial function in 53 subjects with stage I hypertension, abdominal obesity and impaired fasting glucose. The study design was a randomized double-blinded parallel design placebo-controlled multi-centre trial of 8 weeks duration. We used the hyperinsulinaemic–euglycaemic clamp technique to measure insulin sensitivity (expressed as the ‘M/I’ value) and RH-PAT (reactive hyperaemia-peripheral arterial tonometry) to measure endothelial function. Additional measures included HOMA (homoeostasis model assessment)-B, an index of pancreatic β-cell function, and markers of inflammation [e.g. CRP (C-reactive protein)] and oxidative stress (e.g. F2-isoprostanes). ARB therapy did not alter insulin sensitivity [5.2 (2.7) pre-treatment and 4.6 (1.6) post-treatment] compared with placebo therapy [6.1 (2.9) pre-treatment and 5.3 (2.7) post-treatment; P value not significant], but did improve the HOMA-B compared with placebo therapy (P=0.05). ARB therapy also did not change endothelial function [RH-PAT, 2.15 (0.7) pre-treatment and 2.11 (0.7) post-treatment] compared with placebo therapy [RH-PAT, 1.81 (0.5) pre-treatment and 1.76 (0.7) post-treatment; P value not significant]. Markers of inflammation and oxidative stress were not significantly changed by ARB therapy. In conclusion, ARB therapy did not alter peripheral insulin sensitivity or endothelial function in this cohort of patients with essential hypertension, abdominal obesity and impaired fasting glucose, but did improve pancreatic β-cell function.
Skip Nav Destination
Article navigation
Research Article|
October 24 2011
Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose
Todd S. Perlstein;
Todd S. Perlstein
*Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, U.S.A.
Search for other works by this author on:
Robert R. Henry;
Robert R. Henry
†Department of Endocrinology and Metabolism, University of California San Diego, San Diego, CA 92161, U.S.A.
Search for other works by this author on:
Kieren J. Mather;
Kieren J. Mather
‡Division of Endocrinology, Indiana University School of Medicine, Indianapolis, IN 46202-5121, U.S.A.
Search for other works by this author on:
Michael R. Rickels;
Michael R. Rickels
§Division of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, U.S.A.
Search for other works by this author on:
Nicola I. Abate;
Nicola I. Abate
‖Division of Endocrinology and Metabolism, University of Texas Medical Branch, Galveston, TX 77550, U.S.A.
Search for other works by this author on:
Scott M. Grundy;
Scott M. Grundy
¶Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX 75390-9003, U.S.A.
Search for other works by this author on:
Yabing Mai;
Yabing Mai
**Merck Research Laboratories, Merck & Co. Inc., Rahway, NJ 07065, U.S.A.
Search for other works by this author on:
Jeanine B. Albu;
Jeanine B. Albu
††Division of Endocrinology, Diabetes, and Nutrition, St. Luke's Roosevelt Hospital, New York, NY 10025, U.S.A.
Search for other works by this author on:
Jennifer B. Marks;
Jennifer B. Marks
‡‡Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136-1011, U.S.A.
Search for other works by this author on:
James L. Pool;
James L. Pool
§§Department of Medicine, Baylor Clinic, Houston, TX 77030, U.S.A.
Search for other works by this author on:
Mark A. Creager
*Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, U.S.A.
Correspondence: Professor Mark A. Creager (email [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
June 02 2011
Revision Received:
August 15 2011
Accepted:
August 24 2011
Accepted Manuscript online:
August 24 2011
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© The Authors Journal compilation © 2012 Biochemical Society
2012
Clin Sci (Lond) (2012) 122 (4): 193–202.
Article history
Received:
June 02 2011
Revision Received:
August 15 2011
Accepted:
August 24 2011
Accepted Manuscript online:
August 24 2011
Citation
Todd S. Perlstein, Robert R. Henry, Kieren J. Mather, Michael R. Rickels, Nicola I. Abate, Scott M. Grundy, Yabing Mai, Jeanine B. Albu, Jennifer B. Marks, James L. Pool, Mark A. Creager; Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose. Clin Sci (Lond) 1 February 2012; 122 (4): 193–202. doi: https://doi.org/10.1042/CS20110284
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |